Human influenza vaccines and assessment of immunogenicity

Expert Review of Vaccines

Volumn 9, Issue 12, 2010, Pages 1423-1439

  Zakay Rones, Zichria ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

attenuated; experimental; immune responses; inactivated; influenza; vaccines; virus

Indexed keywords

AFLUNOV; ALPHA TOCOPHEROL; AREPANRIX; CHOLESTEROL; DNA VACCINE; FLUCELL; GLYCOPROTEIN; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIPOSOME; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; PREPANDEMIX; SAPONIN; SORBITAN TRIOLEATE; SQUALENE; UNCLASSIFIED DRUG; VIROSOME; VIRUS ANTIGEN; VIRUS SIALIDASE;

CELL CULTURE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; INFLUENZA VIRUS C; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; VIRION; VIRUS HEMAGGLUTINATION; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS STRAIN;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; VIROLOGY;

EID: 78649527527     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.144     Document Type: Review

References (196)

1. Nicholson KG, Wood JM, Zambon M. Infuenza. Lancet 362(9397), 1733-1745 (2003).
2. Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated infuenza vaccine, trivalent in preventing infuenza in young children attending day-care centres. Vaccine 25(47), 8010-8020 (2007).
3. Stohr K. Infuenza-WHO cares. Lancet Infect. Dis. 2(9), 517 (2002).
4. Couch RB. Seasonal inactivated infuenza virus vaccines. Vaccine 26(Suppl. 4), D5-D9 (2008).
5. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal infuenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 58(RR-8), 1-52 (2009).
6. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) infuenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type infuenza A (H1N1), A (H3N2), and B viruses. Vaccine 18(9-10), 899-906 (1999).
7. Skowronski DM, Masaro C, Kwindt TL et al. Estimating vaccine effectiveness against laboratory-confrmed infuenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25(15), 2842-2851 (2007).
8. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The effcacy of infuenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med. 123(7), 518-527 (1995).
9. Ben-Yehuda A, Danenberg HD, Zakay-Rones Z, Gross DJ, Friedman G. The infuence of sequential annual vaccination and of DHEA administration on the effcacy of the immune response to infuenza vaccine in the elderly. Mech. Ageing Dev. 102(2-3), 299-306 (1998).
10. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of infuenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 11(1), 1-5 (1993).
11. Admon D, Engelhard D, Strauss N, Goldman N, Zakay-Rones Z. Antibody response to infuenza immunization in patients after heart transplantation. Vaccine 15(14), 1518-1522 (1997).
12. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing infuenza in the elderly. Cochrane Database Syst. Rev. 2, CD004876 (2010).
13. Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of infuenza virus. Science (NY) 305(5682), 371-376 (2004).
14. Zhou NN, Senne DA, Landgraf JS et al. Genetic reassortment of avian, swine, and human infuenza A viruses in American pigs. J. Virol. 73(10), 8851-8856 (1999).
15. Barr IG, Komadina N, Hurt AC et al. An infuenza A(H3) reassortant was epidemic in Australia and New Zealand in 2003. J. Med. Virol. 76(3), 391-397 (2005).
16. Holmes EC, Ghedin E, Miller N et al. Whole-genome analysis of human infuenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biol. 3(9), e300 (2005).
17. Mossad SB. 2008-2009 Infuenza update: a better vaccine match. Cleve. Clin. J. Med. 75(12), 865-870 (2008).
18. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 infuenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61(1), 94-99 (2000).
19. Palese P, Garcia-Sastre A. Infuenza vaccines: present and future. J. Clin. Invest. 110(1), 9-13 (2002).
20. Wood JM. Selection of infuenza vaccine strains and developing pandemic vaccines. Vaccine 20(Suppl. 5), B40-B44 (2002).
21. Russell CA, Jones TC, Barr IG et al. Infuenza vaccine strain selection and recent studies on the global migration of seasonal infuenza viruses. Vaccine 26(Suppl. 4), D31-D34 (2008).
22. Bianchi E, Liang X, Ingallinella P et al Universal infuenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol. 79(12), 7380-7388 (2005).
23. Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X. Effcacy of live attenuated infuenza vaccine in children against infuenza B viruses by lineage and antigenic similarity. Vaccine 28(9), 2149-2156 (2010).
24. Francis T, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced infuenza A. J. Clin. Invest. 24(4), 536-546 (1945).
25. Wood JM, Mumford J, Schild GC, Webster RG, Nicholson KG. Single-radial-immunodiffusion potency tests of inactivated infuenza vaccines for use in man and animals. Dev. Biol. Standard. 64, 169-177 (1986).
26. Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent infuenza vaccine among elderly subjects. Vaccine 25(44), 7656-7663 (2007).
27. Morag A, Levy R, Weil G, Zakay-Rones Z. Clinical and serological response in humans following immunization with Gripax infuenza vaccine. J. Med. Virol 11(1), 67-75 (1983).
28. Keitel WA, Atmar RL, Cate TR et al Safety of high doses of infuenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166(10), 1121-1127 (2006).
29. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled Phase 3 trial comparing the immunogenicity of high-dose and standard-dose infuenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200(2), 172-180 (2009).
30. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted infuenza viruses for use as live vaccines for man. Adv. Biotechnol. Process. 14, 203-242 (1990).
31. Cox RJ, Brokstad KA, Ogra P. Infuenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated infuenza vaccines. Scand. J. Immunol. 59(1), 1-15 (2004).
32. Buonagurio DA, Bechert TM, Yang CF et al. Genetic stability of live, cold-adapted infuenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 24(12), 2151-2160 (2006).
33. Vesikari T, Karvonen A, Korhonen T et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted infuenza virus vaccine. Pediatr. Infect. Dis. J. 25(7), 590-595 (2006).
34. Buonagurio DA, O'Neill RE, Shutyak L et al. Genetic and phenotypic stability of cold-adapted infuenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 347(2), 296-306 (2006).
35. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal infuenza virus vaccine. J. Infect. Dis. 181(3), 1133-1137 (2000).
36. Belshe RB, Nichol KL, Black SB et al. Safety, effcacy, and effectiveness of live, attenuated, cold-adapted infuenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. 39(7), 920-927 (2004).
37. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated infuenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
38. Belshe RB, Toback SL, Yi T, Ambrose CS. Effcacy of live attenuated infuenza vaccine in children 6 months to 17 years of age. Infuenza Other Resp. Viruses 4(3), 141-145 (2010).
39. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183(11), 6883-6892 (2009).
40. Belshe RB, Gruber WC, Mendelman PM et al. Effcacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal infuenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136(2), 168-175 (2000).
41. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated infuenza vaccine in the United States for seasonal and pandemic infuenza. Infuenza Other Resp. Viruses 2(6), 193-202 (2008).
42. Mendelman PM, Rappaport R, Cho I et al Live attenuated infuenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23(11), 1053-1055 (2004).
43. Renegar KB, Small PA Jr, Boykins LG, Wright PF. Role of IgA versus IgG in the control of infuenza viral infection in the murine respiratory tract. J. Immunol 173(3), 1978-1986 (2004).
44. Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal infuenza vaccines on antibody responses in children. Pediatr. Infect. Dis. J. 22(1), 28-34 (2003).
45. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted infuenza A and B virus vaccines. Viral Immunol. 15(2), 295-323 (2002).
46. Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal infuenza virus vaccine. Emerg. Infect. Dis. 12(4), 569-574 (2006).
47. Couch RB. An overview of serum antibody responses to infuenza virus antigens. Dev. Biol. 115, 25-30 (2003).
48. Potter CW, Oxford JS. Determinants of immunity to infuenza infection in man. Br. Med. Bull. 35(1), 69-75 (1979).
49. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated infuenza whole-virus vaccination. Vaccine 23(11), 1414-1425 (2005).
50. Feng J, Gulati U, Zhang X et al. Antibody quantity versus quality after infuenza vaccination. Vaccine 27(45), 6358-6362 (2009).
51. Nauta JJ, Beyer WE, Osterhaus AD. On the relationship between mean antibody level, seroprotection and clinical protection from infuenza. Biologicals 37(4), 216-221 (2009).
52. Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from infuenza A virus eliminates cognate help and antigenic competition. Virology 225(1), 136-144 (1996).
53. Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal infuenza virus infection by DNA vaccine to neuraminidase. Vaccine 18(28), 3214-3222 (2000).
54. Wu G, Yan S. Prediction of mutation trend in hemagglutinins and neuraminidases from infuenza A viruses by means of cross-impact analysis. Biochem. Biophys. Res. Commun. 326(2), 475-482 (2005).
55. Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of infuenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA 87(2), 786-790 (1990).
56. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2), e59 (2007).
57. Chen Z, Yoshikawa T, Kadowaki S et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding infuenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 80 (Pt 10), 2559-2564 (1999).
58. Varghese JN, Colman PM. Three-dimensional structure of the neuraminidase of infuenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol. 221(2), 473-486 (1991
59. Johansson BE, Bucher DJ, Kilbourne ED. Purifed infuenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63(3), 1239-1246 (1989).
60. Gubareva LV, Kaiser L, Hayden FG. Infuenza virus neuraminidase inhibitors. Lancet 355(9206), 827-835 (2000).
61. Kendal AP, Bozeman FM, Ennis FA. Further studies of the neuraminidase content of inactivated infuenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun. 29(3), 966-971 (1980).
62. Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase antibody response to inactivated infuenza virus vaccine following intranasal and intramuscular vaccination. Isr. Med. Assoc. J. 8(3), 155-158 (2006).
63. Powers DC, Kilbourne ED, Johansson BE. Neuraminidase-specifc antibody responses to inactivated infuenza virus vaccine in young and elderly adults. Clin. Diagn. Lab. Immunol. 3(5), 511-516 (1996).
64. Johansson BE, Pokorny BA, Tiso VA. Supplementation of conventional trivalent infuenza vaccine with purifed viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 20(11-12), 1670-1674 (2002).
65. Webster RG, Campbell CH. An inhibition test for identifying the neuraminidase antigen on infuenza viruses. Avian Dis. 16(5), 1057-1066 (1972).
66. Zalan E, Wilson C, Freitag R. The role of hemagglutinin in the inhibition of neuraminidase activity of infuenza virus by concanavalin A. Brief report. Arch. Virol. 47(2), 177-179 (1975).
67. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Infuenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull. World Health Organ. 48(2), 199-202 (1973).
68. Warren L. The thiobarbituric acid assay of sialic acids. J. Biol. Chem. 234(8), 1971-1975 (1959).
69. Luther P, Klett GE, Weber S, Pechmann H, Bergmann KC. The lectin neuraminidase inhibition test: a new method for the detection of antibodies to neuraminidase. J. Biol. Standard. 11(2), 115-121 (1983). (Pubitemid 13053034)
70. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-a-D-N- acetylneuraminate) substrate. Anal. Biochem. 94(2), 287-296 (1979).
71. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of infuenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71(5), 3385-3390 (1997).
72. Reading PC, Morey LS, Crouch EC, Anders EM. Collectin-mediated antiviral host defense of the lung: evidence from infuenza virus infection of mice. J. Virol. 71(11), 8204-8212 (1997).
73. Tecle T, White MR, Crouch EC, Hartshorn KL. Inhibition of infuenza viral neuraminidase activity by collectins. Arch. Virol. 152(9), 1731-1742 (2007).
74. Erickson AH, Kilbourne ED. Comparative amino acid analysis of infuenza A viral proteins. Virology 100(1), 34-42 (1980).
75. Takahashi T, Suzuki T, Hidari KI, Miyamoto D, Suzuki Y. A molecular mechanism for the low-pH stability of sialidase activity of infuenza A virus N2 neuraminidases. FEBS Lett. 543(1-3), 71-75 (2003).
76. Johansson BE. Immunization with infuenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17(15-16), 2073-2080 (1999).
77. Brett IC, Johansson BE. Variation in the divalent cation requirements of infuenza A virus N1 neuraminidases. J. Biochem. 139(3), 439-447 (2006
78. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. Immunologic response to infuenza virus neuraminidase is infuenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139(6), 2010-2014 (1987
79. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between infuenza A virus surface glycoproteins. Proc. Natl Acad. Sci. USA 84(19), 6869-6873 (1987).
80. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL. Immunologic response to the infuenza virus neuraminidase is infuenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J. Immunol. 138(9), 3010-3013 (1987).
81. Sever JL. Application of a microtechnique to viral serological investigations. J. Immunol. 88, 320-329 (1962).
82. Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to infuenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21(15), 1687-1693 (2003).
83. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted infuenza A/Duck/Singapore/97 vaccine. Virus Res. 103(1-2), 91-95 (2004
84. Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specifcity on erythrocytes affects detection of antibody to avian infuenza haemagglutinin. J. Med. Virol. 70(3), 391-398 (2003).
85. Beyer WE, Palache AM, Sprenger MJ et al. Effects of repeated annual infuenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 14(14), 1331-1339 (1996).
86. Appleyard G, Maber HB. Plaque formation by infuenza viruses in the presence of trypsin. J. Gen. Virol. 25(3), 351-357 (1974).
87. Zakay-Rones Z, Margalith E, Levy R, Katz E. A sensitive plaque inhibition technique for assay of antibodies to infuenza virus: use to detect previous antigenic priming with infuenza viruses. J. Virol. Methods 1(6), 355-360 (1980).
88. Gross PA, Davis AE. Neutralization test in infuenza: use in individuals without hemagglutination inhibition antibody. J. Clin. Microbiol. 10(3), 382-384 (1979).
89. Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live attenuated infuenza vaccine in children. Pediatr. Infect. Dis. J. 23(9), 852-856 (2004).
90. Frank AL, Puck J, Hughes BJ, Cate TR. Microneutralization test for infuenza A and B and parainfuenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 12(3), 426-432 (1980).
91. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian infuenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37(4), 937-943 (1999).
92. Taylor HP, Dimmock NJ. Mechanism of neutralization of infuenza virus by secretory IgA is different from that of monomeric IgA or IgG. J. Exp. Med. 161(1), 198-209 (1985).
93. Asahi Y, Yoshikawa T, Watanabe I et al. Protection against infuenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol. 168(6), 2930-2938 (2002).
94. Boyce TG, Hsu HH, Sannella EC et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit infuenza vaccines administered intranasally to healthy adults. Vaccine 19(2-3), 217-226 (2000).
95. Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-infuenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-1998. J. Clin. Virol. 20(3), 155-161 (2001).
96. Greenbaum E, Furst A, Kiderman A et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-infuenza vaccine. J. Med. Virol. 65(1), 178-184 (2001).
97. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (sIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-infuenza vaccine. Vaccine 22 (20), 2566-2577 (2004).
98. Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated infuenza A virus vaccinations: evidence for immunoglobulin A memory. Infect. Immun. 40(3), 1092-1095 (1983).
99. Voller A, Bidwell DE, Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull. World Health Organ. 53(1), 55-65 (1976).
100. Tamura S, Miyata K, Matsuo K et al. Acceleration of infuenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 156(10), 3892-3900 (1996).
101. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in infuenza infection. Emerg. Infect. Dis. 12(1), 48-54 (2006).
102. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Infuenza virus-specifc cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol 18(6), 529-536 (2007).
103. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to infuenza. N. Engl. J. Med. 309(1), 13-17 (1983).
104. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specifc for infuenza A virus is broad and multispecifc. Hum. Immunol. 61(5), 438-452 (2000).
105. Wraith DC, Vessey AE, Askonas BA. Purifed infuenza virus nucleoprotein protects mice from lethal infection. J. General Virol. 68(Pt 2), 433-440 (1987).
106. Altstein AD, Gitelman AK, Smirnov YA et al. Immunization with infuenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian infuenza viruses. Arch. Virol. 151(5), 921-931 (2006).
107. Fleischer B, Becht H, Rott R. Recognition of viral antigens by human infuenza A virus-specifc T lymphocyte clones. J. Immunol. 135(4), 2800-2804 (1985).
108. Shapira-Nahor O, Morag A, Levy R, Zakay-Rones Z. Cellular response in humans following vaccination with Gripax infuenza virus. J. Med. Virol. 10(1), 75-80 (1982).
109. Shapira-Nahor O, Zakay-Rones Z. Local and peripheral cell-mediated immune response to infuenza virus in mice. J. Med. Virol. 15(1), 81-91 (1985).
110. He XS, Holmes TH, Zhang C et al. Cellular immune responses in children and adults receiving inactivated or live attenuated infuenza vaccines. J. Virol. 80(23), 11756-11766 (2006).
111. Moffat JM, Gebhardt T, Doherty PC, Turner SJ, Mintern JD. Granzyme A expression reveals distinct cytolytic CTL subsets following infuenza A virus infection. Eur. J. Immunol. 39(5), 1203-1210 (2009).
112. Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specifc cytotoxic T-lymphocyte responses to live and inactivated infuenza vaccines. Lancet 2(8252), 887-891 (1981).
113. Epstein SL, Kong W P, Misplon JA et al. Protection against multiple infuenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23(46-47), 5404-5410 (2005).
114. Mabrouk T, Ellis RW. Infuenza vaccine technologies and the use of the cell-culture process (cell-culture infuenza vaccine). Dev. Biol. 110, 125-134 (2002).
115. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human infuenza virus is revealed by haemagglutinin sequence analyses. J. Gen. Virol. 74(Pt 10), 2047-2051 (1993).
116. Oxford JS, Corcoran T, Knott R et al. Serological studies with infuenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull. World Health Organ. 65(2), 181-187 (1987).
117. Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 infuenza viruses. Virology 156(2), 386-395 (1987).
118. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived infuenza vaccine Optafu (Novartis Vaccines). Expert Rev. Vaccines 8(6), 679-688 (2009).
119. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of infuenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20-S23 (1997).
120. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate infuenza virus vaccine. Vaccine 16(9-10), 960-968 (1998).
121. Koudstaal W, Hartgroves L, Havenga M et al. Suitability of PER.C6 cells to generate epidemic and pandemic infuenza vaccine strains by reverse genetics. Vaccine 27(19), 2588-2593 (2009).
122. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of infuenza vaccines. Vaccine 19(17-19), 2716-2721 (2001).
123. European Directorate for the Quality of Medicines. European Pharmacopeaia (3rd Edition), 0159. Council of Europe, Strasbourg, France (1997).
124. Heiny AT, Miotto O, Srinivasan KN et al. Evolutionarily conserved protein sequences of infuenza a viruses, avian and human, as vaccine targets. PloS One 2(11), e1190 (2007).
125. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal infuenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999).
126. Fan J, Liang X, Horton MS et al. Preclinical study of infuenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22(23-24), 2993-3003 (2004).
127. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A 'universal' human infuenza A vaccine. Virus Res. 103(1-2), 173-176 (2004).
128. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Infuenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172(9), 5598-5605 (2004).
129. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits infuenza A virus replication in mice. J. Virol. 64(3), 1375-1377 (1990).
130. Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of infuenza virus-infected SCID mice with nonneutralizing antibodies specifc for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254(1), 138-146 (1999).
131. De Filette M, Min Jou W, Birkett A et al. Universal infuenza A vaccine: optimization of M2-based constructs. Virology 337(1), 149-161 (2005).
132. Hatta M, Kawaoka Y. The NB protein of infuenza B virus is not necessary for virus replication in vitro. J. Virol. 77(10), 6050-6054 (2003).
133. Kemble G, Greenberg H. Novel generations of infuenza vaccines. Vaccine 21(16), 1789-1795 (2003).
134. Paterson RG, Takeda M, Ohigashi Y, Pinto LH, Lamb RA. Infuenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. Virology 306(1), 7-17 (2003).
135. Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of infuenza A virus H1 and H2 strains. J. Virol. 67(5), 2552-2558 (1993).
136. + mediated cellular immune response to recombinant infuenza nucleoprotein. Vaccine 20(31-32), 3731-3738 (2002).
137. Zhirnov OP, Isaeva EI, Konakova TE et al. Protection against mouse and avian infuenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Infuenza Other Resp. Viruses 1(2), 71-79 (2007).
138. Chen Z, Kadowaki S, Hagiwara Y et al. Protection against infuenza B virus infection by immunization with DNA vaccines. Vaccine 19(11-12), 1446-1455 (2001).
139. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based infuenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8(4), 499-508 (2009).
140. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of infuenza A virus from recombinant DNA. J. Virol. 73(11), 9679-9682 (1999).
141. Neumann G, Watanabe T, Ito H et al. Generation of infuenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA 96(16), 9345-9350 (1999).
142. Keitel WA, Treanor JJ, El Sahly HM et al. Comparative immunogenicity of recombinant infuenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons < or = 65 years old. Vaccine 28(2), 379-385 (2009).
143. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against infuenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13(15), 1399-1402 (1995).
144. Cox MM, Karl Anderson D. Production of a novel infuenza vaccine using insect cells: protection against drifted strains. Infuenza Other Resp. Viruses 1(1), 35-40 (2007).
145. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against infuenza by injection of DNA encoding a viral protein. Science (NY) 259(5102), 1745-1749 (1993).
146. Ulmer JB. Infuenza DNA vaccines. Vaccine 20(Suppl. 2), S74-S76 (2002).
147. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian infuenza A virus subtypes with DNA vaccines. Vaccine 18(23), 2592-2599 (2000).
148. Epstein SL, Tumpey TM, Misplon JA et al. DNA vaccine expressing conserved infuenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 8(8), 796-801 (2002).
149. Qiu M, Fang F, Chen Y et al. Protection against avian infuenza H9N2 virus challenge by immunization with hemagglutinin-or neuraminidase-expressing DNA in BALB/c mice. Biochem. Biophys. Res. Commun. 343(4), 1124-1131 (2006).
150. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian infuenza. Vaccine 25(16), 2984-2989 (2007).
151. Choi SY, Suh YS, Cho JH, Jin HT, Chang J, Sung YC. Enhancement of DNA vaccine-induced immune responses by infuenza virus NP gene. Immune Network 9(5), 169-178 (2009).
152. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for infuenza is immunogenic in humans. Vaccine 24(21), 4475-4481 (2006).
153. Musiychuk K, Stephenson N, Bi H et al. A launch vector for the production of vaccine antigens in plants. Infuenza Other Resp. Viruses 1(1), 19-25 (2007).
154. Mett V, Musiychuk K, Bi H et al. A plant-produced infuenza subunit vaccine protects ferrets against virus challenge. Infuenza Other Resp. Viruses 2(1), 33-40 (2008).
155. Tosh PK, Poland GA. Emerging vaccines for infuenza. Expert Opin. Emerg. Drugs 13(1), 21-40 (2008).
156. Mozdzanowska K, Feng J, Eid M et al. Induction of infuenza type A virus-specifc resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21(19-20), 2616-2626 (2003).
157. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based infuenza A virus vaccine in the mouse. Virol. J. 4, 118 (2007).
158. Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian infuenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS One 3(6), e2517 (2008).
159. Arnon A, Levi R. Synthetic recombinant vaccines against viral agents. Int. Arch. Allergy Immunol. 108(4), 321-326 (1995).
160. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of infuenza virus. Vaccine 20(21-22), 2772-2780 (2002).
161. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82(5), 497-505 (2004).
162. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted infuenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 infuenza. Lancet 357(9272), 1937-1943 (2001).
163. Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS One 4(2), e4384 (2009).
164. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted infuenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49(3), 177-184 (2003).
165. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal infuenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
166. Johansen K, Nicoll A, Ciancio BC, Kramarz P. Pandemic infuenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill. 14(41), 19361 (2009).
167. Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit infuenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive infuenza seasons. Vaccine 17(2), 99-104 (1999).
168. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic infuenza prophylaxis. Infuenza Other Resp. Viruses 2(6), 243-249 (2008).
169. Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 infuenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Br. Med. J. 340, c2649 (2010).
170. Malherbe L, Mark L, Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 28(5), 698-709 (2008).
171. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus infuenza vaccine in mice but does not confer superior protection. Vaccine 26(19), 2350-2359 (2008).
172. Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to infuenza vaccine in mice. Vaccine 26(4), 552-561 (2008).
173. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel infuenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine 17(9-10), 1239-1250 (1999).
174. Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel infuenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and effcacy studies in mice. Vaccine 17(9-10), 1223-1238 (1999).
175. Ben-Yehuda A, Joseph A, Zeira E et al. Immunogenicity and safety of a novel liposomal infuenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Virol. 69(4), 560-567 (2003).
176. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13(12), 527-537 (1995).
177. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome infuenza vaccine in elderly people. Lancet 344(8916), 160-163 (1994).
178. Gluck R. Adjuvant activity of immunopotentiating reconstituted infuenza virosomes (IRIVs). Vaccine 17(13-14), 1782-1787 (1999).
179. Zurbriggen R. Immunostimulating reconstituted infuenza virosomes. Vaccine 21(9-10), 921-924 (2003).
180. Plante M, Jones T, Allard F et al. Nasal immunization with subunit proteosome infuenza vaccines induces serum HAI, mucosal IgA and protection against infuenza challenge. Vaccine 20(1-2), 218-225 (2001).
181. Treanor J, Nolan C, O'Brien D et al. Intranasal administration of a proteosome-infuenza vaccine is well-tolerated and induces serum and nasal secretion infuenza antibodies in healthy human subjects. Vaccine 24(3), 254-262 (2006).
182. Rimmelzwaan GF, Baars M, van Beek R et al. Infuenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine 17(20-21), 2512-2516 (1999).
183. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of infuenza vaccine enhances protection by microneedle delivery in the mouse skin. PloS One 4(9), e7152 (2009).
184. Garg S, Hoelscher M, Belser JA et al. Needle-free skin patch delivery of a vaccine for a potentially pandemic infuenza virus provides protection against lethal challenge in mice. Clin. Vaccine Immunol. 14(7), 926-928 (2007).
185. Huang J, Garmise RJ, Crowder TM et al. A novel dry powder infuenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23(6), 794-801 (2004).
186. Mann JF, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral infuenza vaccine delivery vehicle infuences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27(27), 3643-3649 (2009).
187. Quan FS, Kim YC, Vunnava A et al. Intradermal vaccination with infuenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84(15), 7760-7769 (2010).
188. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197-3208 (2008).
189. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Infuenza virus infections in infants. Pediatr. Infect. Dis. J. 16(11), 1065-1068 (1997).
190. Loeb M, Russell ML, Moss L et al. Effect of infuenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 303(10), 943-950 (2010).
191. Rhorer J, Ambrose CS, Dickinson S et al. Effcacy of live attenuated infuenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 27(7), 1101-1110 (2009).
192. Manual on Animal Infuenza Diagnosis and Surveillance. WHO 2002 www.who.int/csr/resources/publications/infuenza/whocdscsrncs20025.pdf
193. European regulations and recommendations www.ema.europa.eu/pdfs/human/ bwp/021496en.pdf
194. US FDA: Guidance for Industry: Characterization and Qualifcation of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications www.fda.gov/downloads/BiologicsBlood Vaccines/GuidanceComplianceRegulatory Information/Guidances/Vaccines/UCM202439. pdfmBio
195. Steel J, Lowen AC, Wang TT et al. Infuenza virus vaccine based on the conserved hemagglutinin stalk domain http://mbio.asm.org/content/1/1/e00018-10. full
196. US FDA: Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Infuenza Vaccines www.fda.gov/BiologicsBlood Vaccines/GuidanceCompliance RegulatoryInformation/Guidances/Vaccines/ucm074794. htm